CeriBell, Inc. (CBLL)

Revenue is scaling quickly with very strong gross margins, but profitability and free cash flow remain deeply negative, so valuation is still mostly a bet on future operating leverage. Liquidity looks solid (the latest 10-Q cites $129.3M cash and marketable securities and at-least-12-month runway) with modest debt, but key risks include reimbursement/regulatory dependence, competition, supply-chain exposure, and patent litigation. Net result: promising adoption and runway, but still execution- and valuation-sensitive until losses narrow materially.

Aug-10 Q2 results and an FDA 510(k) clearance (announced / regulator-confirmed) are the dominant near-term drivers, keeping coverage mildly constructive even as several stories highlight deeper losses and insider selling; the 30–90d baseline sample is too sparse to compute a reliable sentiment delta. Conflicting bullish catalysts versus bearish insider-flow headlines trigger a moderate red-flag cap, while the legal/regulatory screen shows no confirmed investigations.

Strong uptrend with momentum consolidation: price sits above the rising SMA20 (24.22), SMA50 (21.60) and SMA200 (20.19), and ADX14 at 32.2 confirms a strong directional trend. The three-day pullback to a 24.00 swing low is holding above the 09-15 higher low (23.90) and the EMA21 (23.91) — a constructive dip within the trend rather than a breakdown. RSI14 at 56.0 is neutral-positive with room to run before overbought. The one weak signal is momentum cooling: the MACD line (+0.70) is still above zero but below its signal line (+0.87) with a negative histogram, consistent with consolidation — this is what keeps the score at 4 rather than 5. Entry near support with a 1.0×ATR-floored stop yields R/R 2.00.